Project Grant R44DK141357
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$930K
Awardee
Amidebio, LLC (UN9KNR7J6J77)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Biotherapeutics, Inc. a $359,625 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of next-generation, once-daily oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes. Key research objectives include evaluating the therapeutic efficacy of the lead drug candidate on lipid metabolism, insulin...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to evaluate the therapeutic potential of a new orally active small molecule in obesity-linked diabetic models. The $418,560 award, effective September 1, 2024 through April 30, 2025, supports research to: 1) analyze the pharmacokinetic profiles of a new small molecule, 2) investigate the efficacy and...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $990,990 project grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Integrated Medical Sensors Inc., a minority-owned small disadvantaged business located in Irvine, CA. The project aims to optimize the manufacturing and quality framework for the company's miniaturized, integrated continuous glucose monitoring (CGM+) platform in preparation for larger human...
This $310,897 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a first-in-class, islet-targeted antibody therapeutic for Type 1 Diabetes (T1D). The award supports preclinical development and validation activities for this novel antibody therapy, including establishing proof-of-principle for its islet-homing capability, therapeutic...
This $335,410 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a needle-free microneedle array patch (MAP) for delivering a GLP-1 receptor agonist to treat type 2 diabetes. The grant recipient, Vaxess Technologies, Inc., is a biotechnology company specializing in innovative MAP technologies for drug and vaccine...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is dedicated to the development and optimization of non-peptide ligands designed to activate insulin receptors. The $772,383 research project aims to transform approaches to glycemic control in the management of diabetes by uncovering a new generation of receptor modulators that could...
The federal Project Grant award R43DK137616 for $275,766.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds Biosurfaces Inc., a for-profit medical device company, to develop and evaluate an implantable, electrospun cell chamber device loaded with human pancreatic islets. The device aims to provide an immune-protected environment to support...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $199,999 to the University of Florida to develop innovative artificial intelligence (AI)-based methods to support the discovery of potent, orally available small-molecule heparanase inhibitors. The goal is to evaluate these novel heparanase inhibitors in murine models as a...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a novel Diabetes Targeted Dual Neuromodulation (TDN) therapy. The $345,650 grant will fund a Phase I feasibility study by Reshape Lifesciences Inc., a small business joint venture, to validate the hypothesis that decreasing the amplitude of the high frequency...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,428,186.00 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to conduct research on the role of CYP4F enzymes in regulating N-acyl amino acid signaling in humans. The project aims to biochemically characterize N-acyl amino acids as substrates and inhibitors of CYP4F...